Chiesi Group Commences Tender Offer to Acquire KalVista Pharmaceuticals for $27.00 Per Share

summarizeSummary

Chiesi Group has formally launched its tender offer to acquire KalVista Pharmaceuticals for $27.00 per share in cash, a transaction valued at approximately $1.88 billion, with the offer set to expire on June 10, 2026.

check_boxKey Events · M&A and Partnerships · KALV

• Tender Offer Commenced

  Skyline Merger Sub, Inc., a subsidiary of Chiesi Farmaceutici S.p.A., has formally commenced its tender offer to acquire all outstanding shares of KalVista Pharmaceuticals, Inc.

• Acquisition Price Confirmed

  The offer price is $27.00 per share in cash, without interest, consistent with the acquisition agreement announced on April 29, 2026. The total transaction value is approximately $1.88 billion.

• Board Recommendation

  KalVista's Board of Directors has unanimously recommended that shareholders tender their shares in the offer, deeming the transaction fair and in the best interest of the company and its stockholders.

• Subsequent Merger and Delisting

  Following the tender offer, a short-form merger will be completed without a shareholder vote, after which KalVista will become a wholly-owned subsidiary of Chiesi Group and its shares will be delisted from Nasdaq.

auto_awesomeAnalysis · KALV · Life Sciences

This filing marks the formal commencement of the tender offer by Chiesi Group's subsidiary, Skyline Merger Sub, Inc., to acquire all outstanding shares of KalVista Pharmaceuticals for $27.00 per share in cash. This follows the definitive agreement announced on April 29, 2026. The transaction is valued at approximately $1.88 billion and has been unanimously recommended by KalVista's Board of Directors. Upon successful completion of the tender offer, a short-form merger will occur, making KalVista a wholly-owned private subsidiary of Chiesi Group, and its shares will be delisted from Nasdaq.